Journal
CANCER DISCOVERY
Volume 7, Issue 3, Pages 248-249Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-17-0057
Keywords
-
Categories
Funding
- National Institute for Health Research (NIHR) Royal Marsden (RM)/Institute of Cancer Research (ICR) Biomedical Research Centre (BRC)
Ask authors/readers for more resources
FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and colleagues demonstrates that acquisition of gatekeeper mutations in FGFR2 and intratumoral heterogeneity drive resistance in patients with FGFR2 - translocated intrahepatic cholangiocarcinoma, which will have important implications for management of the disease in clinic. (C) 2017 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available